[1] 邓国防,王玉香,陈涛,等. 风湿免疫性疾病并发结核感染的临床特征分析[J]. 中国防痨杂志,2018,40(4):390-394. [2] RUAN Q, ZHANG S, AI J, et al.Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis[J]. Clinical Rheumatology, 2016, 35(2):417-425. [3] GARZIERA G, MORSCH ALB, OTESBELGUE F, et al.Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents[J]. Clinical Rheumatology, 2017, 36(8):1891-1896. [4] 刘涌,朱元珏,高金明. 结缔组织病合并结核92例临床分析[J]. 北京医学, 2009, 31(06):328-331. [5] 刘琳,王仲元,张韬,等. 原发性干燥综合征合并结核病28例临床分析[J]. 中国防痨杂志, 2012, 34(6):384-388. [6] HOCHBERG MC.Updating the American College of Rheumatology revised criteria for the classification systemic lupus erythematosus[J]. Arthritis Rheum, 1997,40(9):1725. [7] BOHAN A, PETER JB.Polymyositis and dermatomyositis[J]. N Engl J Med, 1975, 292(8):344-347. [8] LINDEN SM,VALKENBURG HA,CATS A.Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria[J]. Arthritis Rheum, 1985, 28(4):357. [9] SHIBOSKI SC, SHIBOSKI CH,CRISWELL IA, et al.American College of Rheumatology classification criteria for SjÖgren’s Syndrome: A Data Driven Expert consensus Approach in SjÖgren’s International Collaborative Clinic Alliance cohort[J]. Arthritis Care Res(Hoboken), 2012, 64(4):475-487. [10] ARNETT FC, EDWORTHY SM, BLOCH DA.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988, 31:315-324. [11] 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288—2017)[J/CD]. 新发传染病电子杂志, 2018, 3(1): 65-67. [12] 邓国防, 付亮. 浅谈风湿免疫性疾病并发结核感染的诊治现状[J]. 结核病与肺部健康杂志, 2018, 7(2): 88-90. [13] 左晓霞. 结缔组织疾病患者结核感染的研究现状与思考[J]. 中华风湿病学杂志, 2009, 13(10): 657-659. [14] 唐果. 常见风湿病合并结核感染的临床特点及相关因素分析[D]. 贵州:遵义医科大学, 2019. [15] 依那西普治疗类风湿关节炎和强直性脊柱炎专家组. 依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议(2013)[J].中华医学杂志, 2013, 93(18):29-32. [16] WHO. Global tuberculosis report 2019[M]. Geneva: World Health Organization, 2019. [17] YOUSSEF J, NOVOSAD SA, WINTHROP KL.Infection Risk and Safety of Corticosteroid Use[J]. Rheum DisClin North Am 2016, 42(1):157-176. [18] SARTORI NS, PICON P, PAPKE A, et al.A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment[J]. PloS One, 2019, 14(12):e0224963. [19] DOAN TN, EISEN DP, ROSE MT, et al.Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis[J]. PloS One, 2017, 12(11):e0188631. |